Modus Outcomes' commitment to collaboration and education inspires our bi-annual roundtable events, which we have entitled “Patient-Centered Drug Development: Reflections, Challenges, & Solutions”.

So far we have had held events in Boston, USA, Glasgow, Scotland, New York City, USA, and Barcelona, Spain. At each roundtable, we host prominent experts in the outcomes research field, who share their perspectives on a broad range of issues.  Recent speakers and topics include:

  • Ashley Slagle Reflections on and challenges for regulation in the USA
  • Sophia Kessabi Reflections on and challenges for HTA
  • Susan Bartlett Reflections on and challenges for PCORI / OMERACT / PROMIS
  • John Browne Reflections on and challenges for the efficient use of PROMs in a real-world setting
  • Jean-François Ricci Reflections on and challenges for HTA
  • Anna Mayhew Reflections on and challenges for clinical trials in pediatric rare diseases
  • Bob Massof Functional ability and depression severity after low vision rehabilitation: Quantifying minimum clinically important difference and heterogeneity of treatment effect
  • Peter Hagell Measuring patient-centered outcomes in Parkinson’s disease (PD): On a road to nowhere and back again
  • Sara Smith Using Rasch analysis to understand proxy reports of HRQL in dementia: DEMQOL and DEMQOL-Proxy


At these invite-only events we have been joined by representatives from the pharmaceutical industry and academia including:

  • AbbVie
  • Allergan
  • Alnylam
  • Amgen
  • Astellas
  • Biogen
  • Clovis
  • Eli Lilly
  • Fulcrum
  • Genentech
  • Johns Hopkins University, USA
  • Kirstianstad University, Sweden
  • Lundbeck
  • McGill University, Canada
  • McMaster University, Canada
  • Newcastle University, UK
  • Novartis
  • Novo Nordisk
  • Orphazyme
  • Otsuka
  • Shire
  • Takeda
  • UCB
  • University of California Berkeley, USA
  • University of Cork, Ireland
  • Wellmera